9001 Background: Standard first-line therapy for EGFR mutant advanced non-small cell lung
cancer (NSCLC) is an EGFR-directed oral TKI. We evaluated whether adding pemetrexed …

9005 Background: Although EGFR-TKI alone has been a standard first-line treatment for pts
with advanced NSCLC with EGFR mutations, our phase II study (NEJ005) showed …

PURPOSE Standard first-line therapy for EGFR-mutant advanced non–small-cell lung
cancer (NSCLC) is an epidermal growth factor receptor (EGFR)–directed oral tyrosine …

Background: Although EGFR-TKI alone has been a standard first-line treatment for pts with
advanced NSCLC with EGFR mutations, our phase II study (NEJ005) showed promising …

TPS8131 Background: Based on the previous phase III studies including our NEJ002 study
comparing G with platinum doublet, G alone has been accepted as the standard first-line …

Background NEJ002 study, comparing gefitinib with carboplatin (CBDCA) and paclitaxel
(PTX; Taxol) as the first-line treatment for advanced non-small cell lung cancer (NSCLC) …

Background/Aim: A phase II trial was conducted to assess the efficacy and safety of gefitinib
plus bevacizumab for EGFR mutation-positive non-small cell lung cancer (NSCLC). Patients …

Clinical trials frequently include multiple end points that mature at different times. The initial
report, typically based on the primary end point, may be published when key planned …

Purpose Patients with advanced non-small cell lung cancer (NSCLC) harboring a sensitive
epidermal growth factor receptor (EGFR) mutation have been shown to exhibit a marked …

ABSTRACT EGFR-TKI therapy produces a dramatic clinical response in patients with
NSCLC harboring EGFR mutation. However, clinical outcomes should be improved further …